Pattern of treatment of Reteplase in Myocardial Infarction patient Hospitalized in Shahid Madani Hospital

Abstract

Reteplase is a thrombolytic agent that used to treatment of acute myocardial infarction and is a tissue plasminogen activator which produce plasmin from plasminogen and start to resolve the clot. Rhetplas is a thrombolytic agent used to treat acute myocardial infarction (AMI) (acute myocardial infarction) and is a recombinant tissue plasminogen activator that converts plasminogen directly to plasmin and resolves fibrinolytic activity. Solves begins. Aim: The aim of study is to evaluate the utilization pattern of reteplase in patients with acute myocardial infarction in Shahid Madani Heart Center in 2018. Objective: The aim of this study was to investigate the pattern of drug use in ranking hospitalized in Shahid Madani Hospital in Tabriz in 1397. Materials and Methods: In this prospective cross-sectional study, 102 patients who received reteplase for their acute myocardial infarction who admitted in in Shahid Madani Heart Center in 2018 were evaluated. The utilization pattern of reteplase was compared to the American Heart Association guidelines. Data were analyzed in SPSS 17.0. Results: Totally 102 patients’ medical records were reviewed. Of them, 75 cases were male and 27 cases were female. All patients received two full doses of 18 milligram (10 Units) reteplase. The mean time of two administrations was 29.3 minutes ranged 27 to 32 minutes. Conclusion:Based on the result of present study the utilization pattern of reteplase is compatible with international guidelines.